FCGR2A and neoplasm: The preclinical data presented herein describes a unique binding epitope of ATOR-1017 and the ability of ATOR-1017 to FcγR-conditionally activate T cells and NK cells, which translates into a tumor directed and potent anti-tumor therapeutic effect in vivo that is enhanced in combination with anti-PD-1.